1.1Fibrinogen substrate replacement
A fibrinogen concentrate replenishes circulating fibrinogen when its level is low. Thrombin cleaves the infused fibrinogen, and the resulting fibrin monomers assemble into fibers.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A fibrinogen concentrate replenishes circulating fibrinogen when its level is low. Thrombin cleaves the infused fibrinogen, and the resulting fibrin monomers assemble into fibers.
Intravenous factor XIII concentrate restores the protein available for activation by thrombin in the presence of calcium. Activated factor XIII forms covalent links between fibrin chains and anchors alpha-2-antiplasmin to fibrin, increasing the network's resistance to breakdown.
A dual-barrel applicator combines a concentrated fibrinogen solution and a thrombin solution at the tissue surface. Thrombin converts fibrinogen to fibrin, forming an adherent network over the bleeding site.
Tranexamic acid solution irrigates the socket or wets gauze held against it. Local inhibition of plasminogen binding slows the breakdown of the socket's fibrin clot.
A plasma fibrinogen assay identifies a shortage of substrate for clot formation. Intravenous fibrinogen concentrate or cryoprecipitate supplies fibrinogen for thrombin to convert into fibrin at bleeding sites.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary wound dressing test uses plasma from canine donors to form fibrin clots on porous dressing coupons. Paired coupons receive either an A2 domain solution or its carrier buffer after clot formation. Following a plasmin challenge, a balance records the wet clot mass remaining on each coupon after a fixed drain interval.
Tranexamic acid replaces the A2 domain as the active component in an aqueous formulation. The formulation is added to a preformed fibrin clot before exposure to plasminogen and tissue plasminogen activator. Tranexamic acid occupies lysine-binding sites on plasminogen and reduces its recruitment to fibrin, slowing clot breakdown.
A microplate holds 100 microliters of citrated plasma from a donor with rheumatoid arthritis in each well, with thrombin and calcium added to form clots. Equal aliquots of A2 domain solution are added to separate groups 5, 20, and 40 minutes after clot initiation. Each group has a carrier-only control and receives the same fibrinolytic challenge 10 minutes after treatment. A plate reader measures the time from challenge to a 50 percent decrease in clot-associated turbidity.
A dual-syringe arthroscopic applicator carries fibrinogen mixed with the A2 domain in one barrel and thrombin with calcium in the other. A mixing tip combines the streams as the applicator deposits them onto a prepared joint surface. Thrombin converts fibrinogen into a local scaffold, placing the A2 domain in contact with the fibrin as it forms.
A parallel-plate flow chamber holds a preformed fibrin layer on a removable coverslip. A syringe pump moves A2 domain solution across the layer, followed by a buffer rinse and a fibrinolytic challenge. A fluorescence microscope tracks loss of labeled fibrin over time in paired chambers receiving A2 domain solution or carrier buffer.
A liquid handler dispenses plasma from a donor with rheumatoid arthritis into a microplate and forms matched fibrin clots. It adds a dilution series of the A2 domain to treatment wells and adds carrier buffer to control wells. After a common fibrinolytic challenge, a plate reader records turbidity over time, and software ranks the concentrations by the change in clot half-lysis time relative to the matched controls.
A recombinant expression system produces the isolated A2 domain, and chromatography purifies the soluble protein. A sterile buffered solution delivers the purified domain by intravenous infusion.
A sterile buffered solution carries purified A2 domain to a fibrin-containing wound bed through a blunt applicator. The liquid spreads over the exposed clot and brings the domain into contact with fibrin fibers.
The individual has persistent inflammatory synovitis and circulating antibodies against cyclic citrullinated peptides. A plasma clot-lysis assay measures fibrinolysis separately from the clinical and serologic findings.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In one embodiment of the invention, there is a method of treating and/or preventing sepsis in an individual, comprising delivering to the individual a therapeutically effective amount of an A2 domain of von Willebrand factor, or a fragment of said A2 domain.A · US 2009/0118161 A1 · ¶ 19
The present inventor has investigated the presence of talin in the plasma or the serum of a patient with rheumatoid arthritis.B · US 2016/0109442 A1 · ¶ 11
An empty cell means only that no passage was reproduced there.
The invention is directed to methods to treat, diagnose and/or prevent medical conditions, such as sepsis or thrombosis, utilizing aspects of the A2 domain of von Willebrand factor.A · US 2009/0118161 A1 · ¶ 3
It is a common diagnosis among critically ill patients and carries a high mortality rate.A · US 2009/0118161 A1 · ¶ 4
However, in previous reports, the sensitivity of the rheumatoid factor is 75 to 80%, the specificity thereof is 50 to 70%, and the sensitivity of the anti-CCP antibody is 50 to 75%, and the specificity is 85 to 95%, which are not necessarily satisfactory (see Non-Patent Literatures 2 and 3).B · US 2016/0109442 A1 · ¶ 4
The present invention aims to provide a test method for rheumatoid arthritis and a kit for rheumatoid arthritis test by searching novel markers that have not been previously known and being based on the found novel markers in the searching.B · US 2016/0109442 A1 · ¶ 8
patent.fyi, US 2026/0355289 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355289/, SHA-256 90699d62c8040c74e433665cc6398af9c39b032ffb017d9e08f85b1937969bc5